MolGen B.V. of Veenendaal (NL), a global solutions provider of hardware, reagents, consumables, software and service for human and animal diagnostics, the agriculture and biotech industries, participates in the American Association for Clinical Chemistry Fair (AACC) in Chicago on July 24th - 28th, 2022. The AACC Fair is one of the world’s most important international scientific and medical events for clinical laboratory technologies and research...
At the fair, MolGen presents the PurePrep 24, an DNA/RNA extraction system for high sample volume applications, such as isolating DNA from blood samples. The PurePrep 4800 is a complete DNA/RNA extraction system with sample barcode scanning, liquid handling for reagents and samples, extraction and PCR setup in one system. The newest MolGen testing device is MoaA RT. This multiplex viruses RT-qPCR kit is a single well, which targets 5 highly infectious diseases..
MolGen introduces a new RT-qPCR multiplex kit that combines the detection of five different infectious respiratory viruses, including SARS-CoV-2. The MolGen MoaA RT-q kit is a single well, multiplex RT-qPCR which targets: Influenza A virus, Influenza B virus, Respiratory syncytial viruses (RSV) type A & type B and SARS-CoV-2. These 5 targets represent the most common respiratory threats of this moment...
The rapid spread of SARS-CoV-2 has heavily impacted global society with high pressure of COVID-19 on public health and economics. MolGen is very proud to have assisted in relieving some of the pressure and support the testing framework. Our high-quality nucleic acid extraction kits provide laboratories worldwide with innovative solution for efficient high throughput testing possibilities...
“Automation and industrialization of COVID-19 PCR-testing will facilitate an immense scale-up of the global PCR-testing capacity. It will allow for a new approach to keep society open: preventive, regular testing (twice per week), which will create green bubbles and get us ahead of the curve” - Niels Kruize, CCO, MolGen. To get ahead of the curve, we will need to change our methodology of COVID-19 testing...
MolGen B.V. of Veenendaal (NL) is excited to announce its participation in SLAS 2022, February 5-9. SLAS 2022, organized by SLAS international conference and exhibition to highlight life science discoveries, research and innovations in laboratory technology. With 80 scientific talks and exhibitions, it brings a unique opportunity to inspire life science researchers to share discovery and thought-provoking research, to connect with developers and top-tier providers of laboratory automation...
MolGen B.V. is grounded in its history of developing and marketing advanced bulk chemistry kits for DNA/RNA extraction that successfully satisfied the needs of seed and plant breeding, MolGen today remains committed to finding new ways to advance how it helps those who work in agriculture laboratories. Based in The Netherlands, leveraging from a knowledgeable environment, MolGen has grown in just a few short years and now offers agriculture partners of all sizes a wide range of chemistry tools...
MolGen B.V. is a global solutions provider of innovative DNA / RNA extraction technology, system, products and kits for human and animal diagnostics, agriculture, aquaculture, pharma and biotech, is proud to announce that it has recently opened its UK office. The new office is located at 6th Floor, South Quay Building, 189 Marsh Wall, London, E14 9SH. This expansion will enable the company to meet the rapidly increasing demand for cost-efficient, high quality diagnostic services in new markets...
MolGen B.V., a single-source supplier of DNA/RNA extraction technology and services for the life sciences and biotechnology, announce its entrance into the U.S. market with the launch of MolGen USA, a joint venture with California-based, laboratory automation experts Todaro Robotics. MolGen USA will operate a complete commercial team and product showroom at the San Diego facility....
SpeeDx Pty, Ltd. and MolGen announced the signing of an agreement to collaborate on supply and distribution of clinical diagnostics products and instrumentation across Europe and Asia Pacific. The partnership links specimen handling, nucleic acid extraction, assay set-up, amplification, and results reporting in a seamless integration of the companies technologies...
MolGen B.V. of Veenendaal (NL), a global solutions provider of hardware, reagents, consumables, software and service for human and animal diagnostics, the agriculture and biotech industries, participates in the American Association for Clinical Chemistry Fair (AACC) in Chicago on July 24th - 28th, 2022. The AACC Fair is one of the world’s most important international scientific and medical events for clinical laboratory technologies and research...
At the fair, MolGen presents the PurePrep 24, an DNA/RNA extraction system for high sample volume applications, such as isolating DNA from blood samples. The PurePrep 4800 is a complete DNA/RNA extraction system with sample barcode scanning, liquid handling for reagents and samples, extraction and PCR setup in one system. The newest MolGen testing device is MoaA RT. This multiplex viruses RT-qPCR kit is a single well, which targets 5 highly infectious diseases..
MolGen introduces a new RT-qPCR multiplex kit that combines the detection of five different infectious respiratory viruses, including SARS-CoV-2. The MolGen MoaA RT-q kit is a single well, multiplex RT-qPCR which targets: Influenza A virus, Influenza B virus, Respiratory syncytial viruses (RSV) type A & type B and SARS-CoV-2. These 5 targets represent the most common respiratory threats of this moment...
The rapid spread of SARS-CoV-2 has heavily impacted global society with high pressure of COVID-19 on public health and economics. MolGen is very proud to have assisted in relieving some of the pressure and support the testing framework. Our high-quality nucleic acid extraction kits provide laboratories worldwide with innovative solution for efficient high throughput testing possibilities...
“Automation and industrialization of COVID-19 PCR-testing will facilitate an immense scale-up of the global PCR-testing capacity. It will allow for a new approach to keep society open: preventive, regular testing (twice per week), which will create green bubbles and get us ahead of the curve” - Niels Kruize, CCO, MolGen. To get ahead of the curve, we will need to change our methodology of COVID-19 testing...
MolGen B.V. of Veenendaal (NL) is excited to announce its participation in SLAS 2022, February 5-9. SLAS 2022, organized by SLAS international conference and exhibition to highlight life science discoveries, research and innovations in laboratory technology. With 80 scientific talks and exhibitions, it brings a unique opportunity to inspire life science researchers to share discovery and thought-provoking research, to connect with developers and top-tier providers of laboratory automation...
MolGen B.V. is grounded in its history of developing and marketing advanced bulk chemistry kits for DNA/RNA extraction that successfully satisfied the needs of seed and plant breeding, MolGen today remains committed to finding new ways to advance how it helps those who work in agriculture laboratories. Based in The Netherlands, leveraging from a knowledgeable environment, MolGen has grown in just a few short years and now offers agriculture partners of all sizes a wide range of chemistry tools...
MolGen B.V. is a global solutions provider of innovative DNA / RNA extraction technology, system, products and kits for human and animal diagnostics, agriculture, aquaculture, pharma and biotech, is proud to announce that it has recently opened its UK office. The new office is located at 6th Floor, South Quay Building, 189 Marsh Wall, London, E14 9SH. This expansion will enable the company to meet the rapidly increasing demand for cost-efficient, high quality diagnostic services in new markets...
MolGen B.V., a single-source supplier of DNA/RNA extraction technology and services for the life sciences and biotechnology, announce its entrance into the U.S. market with the launch of MolGen USA, a joint venture with California-based, laboratory automation experts Todaro Robotics. MolGen USA will operate a complete commercial team and product showroom at the San Diego facility....
SpeeDx Pty, Ltd. and MolGen announced the signing of an agreement to collaborate on supply and distribution of clinical diagnostics products and instrumentation across Europe and Asia Pacific. The partnership links specimen handling, nucleic acid extraction, assay set-up, amplification, and results reporting in a seamless integration of the companies technologies...